Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses

Nicholas L. Zalewski, Eoin Flanagan, B Mark Keegan

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective To evaluate specific myelopathy diagnoses made in patients with suspected idiopathic transverse myelitis (ITM). Methods A total of 226 patients 18 years and older were referred to Mayo Clinic Neurology for suspected ITM from December 1, 2010, to December 31, 2015. Electronic medical records were reviewed for detailed clinical presentation and course, laboratory and electrophysiologic investigations, and neuroimaging to determine the etiology. Current diagnostic criteria for ITM and alternative myelopathy diagnoses were applied. All cases where any discrepancy was suspected from the final reported clinical diagnosis were reviewed by each author and a consensus final diagnosis was made. Results The diagnostic criteria for ITM were met in 41 of 226 patients (18.1%). In 158 patients (69.9%), an alternative specific myelopathy diagnosis was made: multiple sclerosis or clinically isolated syndrome, 75; vascular myelopathy, 41; neurosarcoidosis, 12; neuromyelitis optica spectrum disorder, 12; myelin oligodendrocyte glycoprotein myelopathy, 5; neoplastic, 4; compressive, 3; nutritional, 3; infectious, 2; and other, 2. A myelopathy was not confirmed in 27 patients. Time from symptom onset to final clinical diagnosis in patients without ITM was a median of 9 months (range 0-288). Fifty-five patients (24%) required treatment changes according to their final clinical diagnosis. Conclusions The majority of patients with suspected ITM have an alternative specific myelopathy diagnosis. A presumptive diagnosis of ITM can lead to premature diagnostic conclusions affecting patient treatment.

Original languageEnglish (US)
Pages (from-to)e96-e102
JournalNeurology
Volume90
Issue number2
DOIs
StatePublished - Jan 9 2018

Fingerprint

Transverse Myelitis
Spinal Cord Diseases
Myelin-Oligodendrocyte Glycoprotein
Neuromyelitis Optica
Electronic Health Records
Neurology
Neuroimaging
Multiple Sclerosis
Blood Vessels

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. / Zalewski, Nicholas L.; Flanagan, Eoin; Keegan, B Mark.

In: Neurology, Vol. 90, No. 2, 09.01.2018, p. e96-e102.

Research output: Contribution to journalArticle

@article{2dcf6a4ebd9c4fcb906407cfa6822877,
title = "Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses",
abstract = "Objective To evaluate specific myelopathy diagnoses made in patients with suspected idiopathic transverse myelitis (ITM). Methods A total of 226 patients 18 years and older were referred to Mayo Clinic Neurology for suspected ITM from December 1, 2010, to December 31, 2015. Electronic medical records were reviewed for detailed clinical presentation and course, laboratory and electrophysiologic investigations, and neuroimaging to determine the etiology. Current diagnostic criteria for ITM and alternative myelopathy diagnoses were applied. All cases where any discrepancy was suspected from the final reported clinical diagnosis were reviewed by each author and a consensus final diagnosis was made. Results The diagnostic criteria for ITM were met in 41 of 226 patients (18.1{\%}). In 158 patients (69.9{\%}), an alternative specific myelopathy diagnosis was made: multiple sclerosis or clinically isolated syndrome, 75; vascular myelopathy, 41; neurosarcoidosis, 12; neuromyelitis optica spectrum disorder, 12; myelin oligodendrocyte glycoprotein myelopathy, 5; neoplastic, 4; compressive, 3; nutritional, 3; infectious, 2; and other, 2. A myelopathy was not confirmed in 27 patients. Time from symptom onset to final clinical diagnosis in patients without ITM was a median of 9 months (range 0-288). Fifty-five patients (24{\%}) required treatment changes according to their final clinical diagnosis. Conclusions The majority of patients with suspected ITM have an alternative specific myelopathy diagnosis. A presumptive diagnosis of ITM can lead to premature diagnostic conclusions affecting patient treatment.",
author = "Zalewski, {Nicholas L.} and Eoin Flanagan and Keegan, {B Mark}",
year = "2018",
month = "1",
day = "9",
doi = "10.1212/WNL.0000000000004796",
language = "English (US)",
volume = "90",
pages = "e96--e102",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses

AU - Zalewski, Nicholas L.

AU - Flanagan, Eoin

AU - Keegan, B Mark

PY - 2018/1/9

Y1 - 2018/1/9

N2 - Objective To evaluate specific myelopathy diagnoses made in patients with suspected idiopathic transverse myelitis (ITM). Methods A total of 226 patients 18 years and older were referred to Mayo Clinic Neurology for suspected ITM from December 1, 2010, to December 31, 2015. Electronic medical records were reviewed for detailed clinical presentation and course, laboratory and electrophysiologic investigations, and neuroimaging to determine the etiology. Current diagnostic criteria for ITM and alternative myelopathy diagnoses were applied. All cases where any discrepancy was suspected from the final reported clinical diagnosis were reviewed by each author and a consensus final diagnosis was made. Results The diagnostic criteria for ITM were met in 41 of 226 patients (18.1%). In 158 patients (69.9%), an alternative specific myelopathy diagnosis was made: multiple sclerosis or clinically isolated syndrome, 75; vascular myelopathy, 41; neurosarcoidosis, 12; neuromyelitis optica spectrum disorder, 12; myelin oligodendrocyte glycoprotein myelopathy, 5; neoplastic, 4; compressive, 3; nutritional, 3; infectious, 2; and other, 2. A myelopathy was not confirmed in 27 patients. Time from symptom onset to final clinical diagnosis in patients without ITM was a median of 9 months (range 0-288). Fifty-five patients (24%) required treatment changes according to their final clinical diagnosis. Conclusions The majority of patients with suspected ITM have an alternative specific myelopathy diagnosis. A presumptive diagnosis of ITM can lead to premature diagnostic conclusions affecting patient treatment.

AB - Objective To evaluate specific myelopathy diagnoses made in patients with suspected idiopathic transverse myelitis (ITM). Methods A total of 226 patients 18 years and older were referred to Mayo Clinic Neurology for suspected ITM from December 1, 2010, to December 31, 2015. Electronic medical records were reviewed for detailed clinical presentation and course, laboratory and electrophysiologic investigations, and neuroimaging to determine the etiology. Current diagnostic criteria for ITM and alternative myelopathy diagnoses were applied. All cases where any discrepancy was suspected from the final reported clinical diagnosis were reviewed by each author and a consensus final diagnosis was made. Results The diagnostic criteria for ITM were met in 41 of 226 patients (18.1%). In 158 patients (69.9%), an alternative specific myelopathy diagnosis was made: multiple sclerosis or clinically isolated syndrome, 75; vascular myelopathy, 41; neurosarcoidosis, 12; neuromyelitis optica spectrum disorder, 12; myelin oligodendrocyte glycoprotein myelopathy, 5; neoplastic, 4; compressive, 3; nutritional, 3; infectious, 2; and other, 2. A myelopathy was not confirmed in 27 patients. Time from symptom onset to final clinical diagnosis in patients without ITM was a median of 9 months (range 0-288). Fifty-five patients (24%) required treatment changes according to their final clinical diagnosis. Conclusions The majority of patients with suspected ITM have an alternative specific myelopathy diagnosis. A presumptive diagnosis of ITM can lead to premature diagnostic conclusions affecting patient treatment.

UR - http://www.scopus.com/inward/record.url?scp=85044058519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044058519&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004796

DO - 10.1212/WNL.0000000000004796

M3 - Article

C2 - 29247071

AN - SCOPUS:85044058519

VL - 90

SP - e96-e102

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -